Neuroscience
3 Hydroxy 3 Methylglutaryl Coenzyme A
20%
Alzheimer's Disease
48%
Amyloid
30%
Amyloid Protein
9%
Amyotrophic Lateral Sclerosis
66%
Antithrombotic
10%
Astrocyte
19%
Ataxin 2
10%
Atrial Fibrillation
9%
Auras
16%
Autoantibodies
39%
Brain Ischemia
70%
Calcitonin
11%
Capsaicin
9%
Cell Death
10%
Cell Signaling
10%
Central Nervous System
9%
Cerebral Cortex
9%
Cerebral Hemorrhage
18%
Cognitive Disorders
10%
Cyclic Adenosine Monophosphate
14%
Cyclic AMP Responsive Element Binding Protein
14%
Eculizumab
9%
Encephalitis
12%
Encephalopathy
14%
Endoplasmic reticulum
18%
Endoplasmic Reticulum Stress
20%
Fc Receptor
10%
Fluorine-18
13%
Frontotemporal Dementia
34%
Headache
45%
Hematopoietic Stem Cell
10%
Hippocampus
8%
Human Herpesvirus 6
9%
Human Leukocyte Antigen
9%
Immunoprecipitation
9%
In Vivo
29%
Interleukin 6
19%
Ischemia
38%
JC Virus
13%
Kinase
9%
L-DOPA
13%
Magnetic Resonance Imaging
11%
Magnetic Resonance Imaging
9%
Meta-Analysis
9%
Metabolic Pathway
17%
Methylprednisolone
8%
Microglia
17%
Middle Cerebral Artery
22%
Migraine
81%
Motor Neuron
15%
Motor Neuron Disease
10%
Multiple Sclerosis
52%
Muscle Atrophy
10%
Muscle Disorder
86%
Myasthenia gravis
100%
Myelinogenesis
9%
Myelitis
14%
Myositis
41%
Natalizumab
9%
Nervous System Disorder
14%
Neurodegeneration
14%
Neurodegenerative Disorder
15%
Neuromuscular
10%
Nitric Oxide
11%
Ofatumumab
10%
Oligodendrocyte
31%
Oligodendrocyte Progenitor
16%
Optogenetics
14%
Parkinson's Disease
53%
Placebo
11%
Positron Emission Tomography
27%
Prednisolone
12%
Progenitor Cell
13%
Progressive Multifocal Leukoencephalopathy
23%
Protein Binding
9%
Protein Phosphorylation
11%
Ptosis (Eyelid)
9%
Ravulizumab
14%
Remyelinization
12%
Response Element
9%
RNA-binding Protein
22%
Secondary Progressive Multiple Sclerosis
8%
Serotonin
9%
Signal Recognition Particle
31%
Single-Photon Emission Computed Tomography
25%
Spreading Cortical Depression
48%
STAT3
9%
Statin
8%
Stem Cell
28%
Striatum
12%
Subjective Cognitive Decline
9%
T Cell
12%
TAR DNA Binding Protein
22%
Tauopathy
9%
Transverse Myelitis
14%
Treatment of Multiple Sclerosis
9%
Trigeminal Ganglion
10%
Ubiquitin
14%
Upper Motor Neuron
10%
Medicine and Dentistry
(3 Iodobenzyl)guanidine
9%
Adverse Event
11%
Alteplase
10%
Alzheimer's Disease
20%
Amino Acid Transfer RNA Ligase
11%
Amyloid
14%
Amyotrophic Lateral Sclerosis
7%
Antiplatelet
7%
Antisynthetase Syndrome
19%
Apoplexy
26%
Aquaporin 4 Antibody
6%
Atrial Fibrillation
14%
Autoantibodies
15%
Brain Infarction
9%
Brain Ischemia
30%
Calcitonin Gene Related Peptide
16%
Capillary
9%
Cell Culture
7%
Central Nervous System
11%
Cerebral Hemorrhage
28%
Cerebrospinal Fluid
14%
Cerebrovascular Disease
6%
Cluster Headache
9%
Cohort Analysis
15%
Cortical Spreading Depression
18%
COVID-19
19%
Cross Sectional Study
10%
Dermatomyositis
7%
Diagnosis
8%
Direct Oral Anticoagulant
8%
Disease
21%
Drug Megadose
6%
Drug Therapy
6%
Endoplasmic reticulum
8%
Endoplasmic Reticulum Stress
9%
Enzyme Linked Immunosorbent Assay
7%
Galcanezumab
6%
Glucocorticoid
6%
Hazard Ratio
7%
Headache
41%
HMG-CoA
15%
Human Herpesvirus 6
9%
Immune Checkpoint Inhibitor
7%
Immunoprecipitation
9%
Immunotherapy
6%
Inclusion Body Myositis
9%
Infection
11%
Interictal Period
7%
Interim Analysis
9%
JC Virus
7%
Magnetic Resonance Imaging
6%
Mechanical Thrombectomy
15%
Methylprednisolone
12%
Migraine
64%
Migraine Treatment
8%
Mild Cognitive Impairment
7%
Monoclonal Antibody
16%
Motor Neuron Disease
9%
Multiple Chronic Conditions
14%
Multiple Sclerosis
24%
Muscle Biopsy
10%
Muscle Disease
12%
Muscular Dystrophy
7%
Myasthenia
6%
Myasthenia gravis
52%
Myopathy
43%
Myositis
30%
Neoplasm
6%
Neurologic Disease
22%
Neurology
18%
Neuromyelitis Optica
23%
Nivolumab
9%
Oxidoreductase
22%
Pain Assessment
9%
Parkinson's Disease
17%
Parkinsonism
9%
Patient Population
6%
Placebo
8%
Prednisolone
9%
Prevalence
8%
Progressive Multifocal Leukoencephalopathy
9%
Quality of Life
13%
Radiation Therapy
9%
Ravulizumab
14%
Retrospective Study
9%
RNA Editing
9%
Satralizumab
14%
Sequela
6%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
Signal Recognition Particle
13%
Single-Photon Emission Computed Tomography
9%
Surgery
7%
Symptom
18%
T Cell
9%
Thymoma
16%
Transverse Myelitis
9%
Vertebral Artery Dissection
9%
Warfarin
12%
Weakness
8%
Yokukansan
9%
Keyphrases
Acetylcholine Receptor Antibody
9%
Acute Ischemic Stroke
5%
Acute Phase
7%
Age of Onset
5%
Aging
8%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
6%
Alternative Interventions
9%
Anti-Kv1.4 Antibody
6%
Anti-signal Recognition Particle Antibody
11%
Anti-striational Antibodies
12%
Antisynthetase Syndrome
7%
Autoantibodies
18%
CAMP Response Element-binding Protein
9%
Central Nervous System
6%
Cerebral Blood Flow
7%
Cerebral Ischemia
9%
Cerebrovascular Disease
6%
Clinical Characteristics
8%
Clinical Features
10%
Coenzyme A
6%
Comorbidity
9%
Confidence Interval
10%
Cortical Spreading Depression
14%
Endoplasmic Reticulum
7%
Favorable Outcome
9%
Fc Receptor
10%
Galcanezumab
6%
Human Herpesvirus 6 (HHV-6)
9%
Idiopathic Inflammatory Myopathies
16%
Inclusion Bodies
9%
Interim Analysis
9%
Ischemia
9%
Ischemic Cerebrovascular Disease
14%
Ischemic Stroke
6%
Istradefylline
9%
Japan
59%
Japanese Patients
17%
Japanese Population
11%
Japanese Society of Neurology
9%
Kawasaki
6%
Kv1.4
7%
Lasmiditan
9%
Mature Oligodendrocyte
7%
Mechanical Thrombectomy
9%
Methylprednisolone
10%
Migraine
21%
Minimal Manifestations
17%
Motor Neuron Disease
6%
Multiple Sclerosis
5%
Multiple Sclerosis Lesions
7%
Multiple Sclerosis Treatment
11%
Muscle-specific Kinase Antibody
9%
Myasthenia Gravis
89%
Myasthenic
10%
Myelination
9%
Myelitis
9%
Myocarditis
14%
Myopathy
17%
Myositis
29%
Natalizumab
9%
Necrotizing Myopathy
6%
Neurological Diseases
14%
Neurology
14%
Neuromyelitis Optica Spectrum Disorder (NMOSD)
23%
Nivolumab
10%
Nucleic Acid Therapeutics
7%
Oligodendrocyte Precursor Cell Differentiation
6%
Oligodendrocyte Precursor Cells
14%
Oral Prednisolone
8%
Patients with multimorbidity
7%
Peri-infarct Area
10%
Phosphorylated Signal Transducer and Activator of Transcription 3
6%
Placebo
10%
Polymorphism
9%
Post-marketing Surveillance
9%
Prednisolone
6%
Programmed Death-ligand 1 (PD-L1)
7%
Rat Brain
9%
Ravulizumab
14%
Recirculation
8%
Reductase
11%
Relapsing-remitting multiple Sclerosis
7%
RNA Immunoprecipitation
7%
Ropinirole Hydrochloride
9%
Satralizumab
14%
Seipin
9%
Seipinopathy
9%
Serum Samples
6%
Severe Disease
6%
Skeletal muscle
6%
Spreading Depolarization
14%
Striational Antibodies
8%
Stroke Data
9%
Subgroup Analysis
9%
Temporal Profile
9%
Thymoma
21%
Thymoma-associated Myasthenia Gravis
6%
Transient Middle Cerebral Artery Occlusion (tMCAO)
6%
Well-being
6%
Zilucoplan
9%